Kedarnath Nanjund Sastry

This inventor holds 19 USPTO granted patents and 1 published patent application, plus 7 CIPO patents and 11 EPO patents, primarily in Immunomodulatory Proteins. Top assignees: Biocon Limited, Centro De Inmunologia Molecular, Biocon Limited & Centro De Immunologia Molecular. Active years: 2012-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kedarnath Nanjund Sastry. Retrieved from https://idiyas.com/inventor/kedarnath-nanjund-sastry

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19 (Patent Applications = 1)

% Patents Active = 89.5

CIPO Patents = 7 (Patent Applications = 1)

EPO Patents = 11 (Patent Applications = 8)

Average Co-Inventor Count = 4.5

ph-index = 6

Forward Citations = 86(Granted Patents)

Location History:

Bengaluru, IN (2012 - 2024)
Karnataka, IN (2013 - 2024)

Company Filing History:

Centro De Inmunologia Molecular

patents

1 out of 1

Biocon Limited & Centro De Immunologia Molecular

patent

4. 1 out of 8

Centro De Immunologia Molecular

patents

5. 1 out of 1

Centro De Inmunolgia Molecular

patent

where one patent can have more than one assignee

Years Active: 2012-2025

Loading Chart...

Areas of Expertise:

Fusion Proteins

Immunomodulatory

Monoclonal Antibodies

EGFR Targeting

CTLA4 Antibody

Cancer Treatment

Insulin Compounds

Biologically Active Polypeptides

Glycosylation Reduction

Targeted Therapy

TGF-βRII

Protein Expression

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12351636 - Fusion immunomodulatory proteins and methods for making same (2025-07-08),

2. 12049632 - Anti-EGFR1-PD1 targeted/immunomodulatory fusion protein (2024-07-30),

3. 11981743 - Monoclonal antibody and a method thereof (2024-05-14),

4. 11028399 - CTLA4/PD1 targeted/immunomodulatory fusion proteins (2021-06-08),

5. 10669346 - Monoclonal antibody and a method thereof (2020-06-02),

6. 10385348 - Epidermal growth factor receptor targeted/immunomodulatory fusion proteins and methods of use for them (2019-08-20),

7. 10144934 - Targeted/TGF-ßRII fusion proteins and methods for making same (2018-12-04),

8. 10000573 - Monoclonal antibody and a method thereof (2018-06-19),

9. 9809651 - Method of treating cancer with an EGFR targeted immunomodulatory fusion protein (2017-11-07),

10. 9758582 - Anti-CTLA4 antibody-TGF-βRII targeted/immunomodulatory fusion proteins (2017-09-12),

11. 9670285 - Monoclonal antibody and a method thereof (2017-06-06),

12. 9340617 - Targeted/immunomodulatory fusion proteins and methods for making same (2016-05-17),

13. 9217037 - Monoclonal antibody and a method thereof (2015-12-22),

14. 9090705 - Process for preparation of insulin compounds (2015-07-28),

15. 8975041 - Fusion proteins and method of expression thereof (2015-03-10),

Title: Kedarnath Nanjund Sastry: A Pioneer in Cancer Therapy Innovations

Introduction

Kedarnath Nanjund Sastry, based in Bengaluru, India, is an influential figure in the field of biotechnology and pharmaceuticals. With an impressive portfolio of 18 patents, he has made significant contributions to cancer therapy through his innovative inventions. His work reflects a commitment to advancing medical science and improving patient outcomes.

Latest Patents

Among his most recent patents, Kedarnath Nanjund Sastry has developed an "Anti-EGFR1-PD1 targeted/immunomodulatory fusion protein." This invention focuses on creating fusion proteins effective for cancer therapy. It combines targeting moieties and immunomodulatory elements that help counteract the immune tolerance exhibited by cancer cells. Another notable patent is a "Monoclonal antibody and a method thereof." This invention pertains to a humanized IgG1 isotype anti-CD6 antibody (T1h) that interacts with the Scavenger receptor cysteine-rich domain. It aims to improve therapeutic strategies involving thymic epithelial cells and activated T cells.

Career Highlights

Kedarnath has built his career in esteemed organizations that enhance his expertise in biotechnology. Notably, he has worked with Biocon Limited, one of India's leading biopharmaceutical companies. Additionally, his tenure at Centro De Inmunologia Molecular further solidified his research capabilities in immunotherapy and related fields.

Collaborations

Throughout his career, Kedarnath Nanjund Sastry has collaborated with several notable professionals in his field. His coworkers, Nagaraj Govindappa and Maria Melina Soares, have also contributed to various projects and research initiatives alongside him. Such collaborations highlight the importance of teamwork in driving innovation and achieving scientific breakthroughs.

Conclusion

Kedarnath Nanjund Sastry stands out as a prominent inventor whose work in cancer therapy is paving the way for future advancements in medical treatments. With his numerous patents and collaborations, he continues to make significant strides in the biotechnology sector, positively impacting patients and healthcare systems worldwide. His dedication to innovation exemplifies the role of inventors in tackling complex health challenges through creative solutions.

Profile summary based on public USPTO records.